Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Pharmaust Limited ( (AU:NUZ) ) has issued an announcement.
Neurizon Therapeutics Limited has announced the application for the quotation of 150,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code NUZ. This move is part of the company’s strategy to enhance its capital structure and market presence, potentially impacting its operations and positioning within the industry.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Average Trading Volume: 775,672
Technical Sentiment Signal: Sell
Current Market Cap: A$58.8M
Find detailed analytics on NUZ stock on TipRanks’ Stock Analysis page.